載入中
NASDAQHealthcareBiotechnology
最新資料
US$30.65
+US$0.80 · +2.68%
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
前收盤價
US$30.65
+US$0.80 · +2.68%
盤中時間採用ET。市場資料可能有所延遲。
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
日內區間
目前US$30.65
52週區間
目前US$30.65
盤中時間採用ET。市場資料可能有所延遲。
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
日內區間
目前US$30.65
52週區間
目前US$30.65
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 銷貨成本 | — | — | — | 1.5萬 USD |
| 毛利 | — | — | — | −1.5萬 USD |
| 研究與開發 | 9478.9萬 USD | 6093.5萬 USD | 2799.9萬 USD | 911.5萬 USD |
| 銷售、一般及管理費用 | 3031萬 USD | 2212萬 USD | 818萬 USD | 136.58萬 USD |
| 營業費用 | 1.25億 USD | 8305.5萬 USD | 3617.9萬 USD | 1035.2萬 USD |
| 利息收入 | 1361.6萬 USD | 1213.8萬 USD | 252.7萬 USD | — |
| 利息支出 | — | — | — | 28.5萬 USD |
| 折舊和攤銷 | 101.7萬 USD | 83.9萬 USD | 11.2萬 USD | 1.5萬 USD |
| 營業利益 | −1.25億 USD | −8305.5萬 USD | −3617.9萬 USD | −1036.7萬 USD |
| 淨利 | −1.11億 USD | −7830.7萬 USD | −3478.6萬 USD | −1065.2萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$67.00
上漲空間 118.60%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4802.41萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2409.27萬0.03%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1619.79萬0.02%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO857.17萬0.05%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO790.35萬0.06%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB664.58萬0.06%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS602.22萬0.02%338.69億 USD0.31%US$78.35+0.32%
State Street SPDR S&P Pharmaceuticals ETFXPH592.67萬1.28%4.62億 USD0.35%US$64.65+1.60%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASState Street SPDR S&P Pharmaceuticals ETFXPHAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
